MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.bcp.2024.116571

Медицинская библиотека · Biochemical pharmacology · 2024

Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction.

Moraña-Fernández Sandra, Vázquez-Abuín Xocas, Aragón-Herrera Alana, Anido-Varela Laura, García-Seara Javier, Otero-García Óscar, Rodríguez-Penas Diego, Campos-Toimil Manuel, Otero-Santiago Manuel, Rodrigues Alexandre, Gonçalves Alexandre, Pereira Morais Juliana, Alves Inês N, Sousa-Mendes Cláudia, Falcão-Pires Inês, González-Juanatey José Ramón, Feijóo-Bandín Sandra, Lago Francisca

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

The promising results obtained in the PARADIGM-HF trial prompted the approval of sacubitril/valsartan (SAC/VAL) as a first-in-class treatment for heart failure with reduced ejection fraction (HFrEF) patients. The effect of SAC/VAL treatment was also studied in patients with heart failure with preserved ejection fraction (HFpEF) and, although improvements in New York Heart Association (NYHA) class, HF hospitalizations, and cardiovascular deaths were observed, these results were not so promising. However, the demand for HFpEF therapies led to the approval of SAC/VAL as an alternative treatment, although further studies are needed. We aimed to elucidate the effects of a 9-week SAC/VAL treatment in cardiac function and metabolism using a preclinical model of HFpEF, the Zucker Fatty and Spontaneously Hypertensive (ZSF1) rats. We found that SAC/VAL significantly improved diastolic function parameters and modulated respiratory quotient during exercise. Ex-vivo studies showed that SAC/VAL treatment significantly decreased heart, liver, spleen, and visceral fat weights; cardiac hypertrophy and percentage of fibrosis; lipid infiltration in liver and circulating levels of cholesterol and sodium. Moreover, SAC/VAL reduced glycerophospholipids, cholesterol, and cholesteryl esters while increasing triglyceride levels in cardiac tissue. In conclusion, SAC/VAL treatment improved diastolic and hepatic function, respiratory metabolism, reduced hypercholesterolemia and cardiac fibrosis and hypertrophy, and was able to modulate cardiac metabolic profile. Our findings might provide further insight into the therapeutic benefits of SAC/VAL treatment in obese patients with HFpEF.

Для цитирования: Moraña-Fernández Sandra, Vázquez-Abuín Xocas, Aragón-Herrera Alana, Anido-Varela Laura, García-Seara Javier, Otero-García Óscar, Rodríguez-Penas Diego, Campos-Toimil Manuel, Otero-Santiago Manuel, Rodrigues Alexandre, Gonçalves Alexandre, Pereira Morais Juliana, Alves Inês N, Sousa-Mendes Cláudia, Falcão-Pires Inês, González-Juanatey José Ramón, Feijóo-Bandín Sandra, Lago Francisca. Cardiometabolic effects of sacubitril/valsartan in a rat model of heart failure with preserved ejection fraction.. Biochemical pharmacology. 2024. DOI: 10.1016/j.bcp.2024.116571.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.